Company intelligence / Profile preview

Georgiamune

Gaithersburg, Maryland, United Statesgeorgiamune.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Georgiamune has advanced two first-in-class clinical assets into human trials within five months of each other. GIM‑122, a dual-functioning monoclonal antibody designed to overcome immunotherapy resistance in cancer patients, received IND clearance in August 2023. GIM‑531, an oral small molecule that selectively inhibits T-regulatory cells to restore anti-tumor immunity, received IND clearance in May 2024. Both are being tested for safety and efficacy in advanced solid tumors. The company claims three drugs are already undergoing clinical trials with more under development.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodies (mAbs)Small molecules (oral therapies)Immunomodulators
Industry: Biotech

Drug pipeline

9 assets

GIM-531

8 more assets in the full pipeline.

Request access →

Partnerships

Parker Institute for Cancer Immunotherapy among investors; no explicit pharma partnerships disclosed but strong academic roots noted.

Beyond the preview

Go deeper on Georgiamune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Georgiamune.

Explore the full profile